GlassScriptPhysician profile
Jennifer Lundgren
NPI 1215093869
$3,910.56
in general payments reported to CMS, 2019-2025
24 companies · $794 in 2025
The $794 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,017 · 2020: $194 · 2021: $42.67 · 2022: $184 · 2023: $647 · 2024: $1,032 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,472.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $796.62 | 2019-2025 | |
| Novo Nordisk INC | $619.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $540.93 | 2019-2025 | Evenity, Repatha, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $375.23 | 2019-2025 | Jardiance |
| Abbvie INC. | $259.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $242.87 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $232.24 | 2019-2025 | Farxiga, Fasenra |
| Exact Sciences Corporation | $170.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $123.43 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $117.01 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $85.89 | 2019-2022 | |
| Lilly USA, LLC | $48.18 | 2024-2025 | Zepbound |
| Dexcom, INC. | $43.59 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $30.39 | 2019-2023 | |
| Edwards Lifesciences Corporation | $30.34 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $29.72 | 2022 | |
| Idorsia Pharmaceuticals US INC | $28.95 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $24.12 | 2025 | Aptima |
| Astellas Pharma US INC | $22.55 | 2019 | |
| Medtronic USA, INC. | $19.78 | 2019 | |
| Sanofi Pasteur INC. | $18.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.40 | 2019 | |
| Therapeuticsmd, INC. | $16.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lundgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.